… the study, which AstraZeneca funded and in February said … 256 people with advanced breast cancer positive for hormone … 40% of patients whose breast cancer is responsive to … receptor-positive, HER2-negative breast cancer progressed following initial treatment …

… could stop some breast cancer tumours from using hormones … from getting into the breast cancer cell, which researchers … funded by AstraZeneca, looked at patients with hormone-positive, HER2-negative breast cancer … UK reports that breast cancer is the most common …

… focused on people whose breast cancers are fueled by estrogen. … stimulate cancer growth. AstraZeneca funded the clinical trial, … , people with metastatic breast cancer now live about five … with estrogen-driven metastatic breast cancer since 2013, called the …

… diagnosed with primary breast cancer at 38 and incurable secondary breast cancer at 41 … continue calling for improvements in breast cancer diagnostics for women like Lucy … top priority by significantly increasing funding and keeping promises on speedy …

… the growth of certain breast cancer tumours, offering hope to … hormone-positive, HER2-negative breast cancer, which accounts for approximately … the study, which was funded by AstraZeneca and co … “a pivotal moment in breast cancer care”. Professor Kristian Helin, …

… drug can help stop certain breast cancer tumours before they grow, … hormone-positive, HER2-negative breast cancer, which is about 70% … the study, which was funded by AstraZeneca and co-led … is “a pivotal moment in breast cancer care”. Professor Kristian Helin, …

… (ER)–positive, HER2-negative metastatic breast cancer following disease progression on frontline … chair of the British Columbia Breast Tumor Group. Exploring the Study Design … Pfizer. He also received research funding from AstraZeneca, Novartis, and Pfizer …

… life-changing battle with breast cancer  Opal who always … she was diagnosed with breast cancer in her teens. … , she held conversations with breast cancer survivors, doctors, and WHO … collection is used to fund breast cancer initiatives. Sharing the message …

… ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation. … ER-positive, HER2-negative advanced breast cancer compared with fulvestrant, according to … Novartis and Pfizer; and research funding from AbbVie, Arvinas, AstraZeneca, BeiGene …

… an aggressive form of breast cancer, potentially extending their lives … 2 negative (HER2-) breast cancer, a condition where a … giving people with metastatic breast cancer the opportunity to live … our funded scientists have been making at the Breast Cancer Now …